» Articles » PMID: 20655393

Colorectal Cancers Detected After Colonoscopy Frequently Result from Missed Lesions

Overview
Specialty Gastroenterology
Date 2010 Jul 27
PMID 20655393
Citations 90
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Colorectal cancers (CRCs) that are detected in patients who have received colonoscopies (interval cancers) arise from missed lesions, incomplete resections of adenomas, or de novo. We estimated rates of interval cancer from missed lesions.

Methods: Adenoma miss rates, cancer prevalence among patients with adenoma (based on size), and rates of adenoma-to-cancer transitions were estimated from the literature. We used a model to apply these risk estimates to a hypothetical average-risk population that received screening colonoscopies. We calculated the proportion of individuals with tumors missed at the baseline colonoscopy and tumors that arose from missed adenomas during a 5-year follow-up period. Sensitivity analyses were performed to assess robustness.

Results: We found that 0.7 per 1000 persons undergoing a screening colonoscopy had a cancer that was missed at the baseline colonoscopy and an additional 1.1 per 1000 subsequently developed cancer from a missed adenoma. Therefore, the expected rate of individuals with CRC, based on missed adenomas, was 1.8 per 1000 persons within 5 years. By using the most conservative assumptions-a low miss rate and low prevalence of cancer in adenomas-0.5 per 1000 persons would have a detectable CRC within 5 years after a screening colonoscopy. In contrast, using the highest reported miss rates and cancer prevalence, CRCs from missed lesions would occur in 3.5 per 1000 screened persons.

Conclusions: A significant number of patients undergoing a screening colonoscopy that did not detect cancer actually have a malignant lesion or adenoma that could progress in a short interval. Most interval cancers might reflect missed rather than new lesions. Improving adenoma detection could reduce the rate of interval cancers.

Citing Articles

Injecting hope: the potential of intratumoral immunotherapy for locally advanced and metastatic cancer.

Skalickova M, Hadrava Vanova K, Uher O, Leischner Fialova J, Petrlakova K, Masarik M Front Immunol. 2025; 15:1479483.

PMID: 39850897 PMC: 11754201. DOI: 10.3389/fimmu.2024.1479483.


Colorectal cancer: local results and significance in Hungary.

Longobardi S J Gastrointest Oncol. 2025; 15(6):2552-2577.

PMID: 39816032 PMC: 11732334. DOI: 10.21037/jgo-24-318.


Colonoscopy Remains an Important Option for Primary Screening for Colorectal Cancer.

Rex D Dig Dis Sci. 2024; .

PMID: 39666212 DOI: 10.1007/s10620-024-08760-8.


Exploring the feasibility of home-delivered capsule endoscopy with 5G support: innovations and carbon footprint insights.

Jalayeri Nia G, Conway C, Ward F, Dungey S, Streames L, Liu B BMJ Open Gastroenterol. 2024; 11(1).

PMID: 39486797 PMC: 11529455. DOI: 10.1136/bmjgast-2024-001500.


Endoscopist adenomas-per-colonoscopy detection rates and risk for postcolonoscopy colorectal cancer: data from the New Hampshire Colonoscopy Registry.

Anderson J, Rex D, MacKenzie T, Hisey W, Robinson C, Butterly L Gastrointest Endosc. 2023; 99(5):787-795.

PMID: 37993057 PMC: 11039365. DOI: 10.1016/j.gie.2023.11.014.